October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
September 2025 in “Value in Health”
April 2018 in “Journal of Investigative Dermatology” Cutaneous lupus patients have higher levels of certain immune cells in their blood and skin.
January 2026 in “Vestnik dermatologii i venerologii” Tacrolimus ointment is effective for various skin conditions but needs more research for long-term effects.
73 citations
,
March 2014 in “Journal of The American Academy of Dermatology” Most dermatologic medications are safe during pregnancy and breastfeeding, but some should be avoided due to potential risks.
August 2023 in “European journal of dermatology/EJD. European journal of dermatology” Combining topical delgocitinib with a 308-nm excimer laser can effectively treat severe alopecia areata and vitiligo.
March 2026 in “British Journal of Dermatology” Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.
26 citations
,
October 2018 in “Clinical & Translational Oncology” Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
Ritlecitinib significantly regrows scalp hair in people with alopecia areata.
5 citations
,
May 2023 in “Clinical Rheumatology” Tofacitinib helped regrow hair in a lupus patient with alopecia.
30 citations
,
August 2010 in “American Journal of Clinical Dermatology” Cetuximab can cause eyelash growth, which is rare but manageable.
Belimumab may cause hair loss in lupus patients.
January 2009 in “Epsilon: Revista de la Sociedad Andaluza de Educación Matemática "Thales"” A CCS patient with severe complications was successfully treated using combined therapies.
6 citations
,
March 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective for long-term treatment of severe alopecia areata.
3 citations
,
June 2018 in “Internal Medicine” Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.
53 citations
,
August 2014 in “Cochrane library” Methotrexate is not proven effective for inducing remission in ulcerative colitis.
1 citations
,
September 2022 in “TURKDERM” Systemic retinoids do not increase COVID-19 risk or severity.
8 citations
,
April 2006 in “Acta dermato-venereologica” Dovobet ointment used overnight effectively reduces scalp psoriasis severity and itch.
October 2023 in “Journal of cystic fibrosis” 18 citations
,
October 2019 in “European Journal of Dermatology” 23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
12 citations
,
July 2023 in “Journal of the European Academy of Dermatology and Venereology” Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
2 citations
,
March 2025 in “International Journal of Dermatology” Tralokinumab successfully treated alopecia areata in a patient with atopic dermatitis.